Top

Published in:

01-05-2009 | Review

An association between invasive breast cancer and familial idiopathic hyperparathyroidism: a case series and review of the literature

Authors: Sumanta Kumar Pal, Kathleen Blazer, Jeffrey Weitzel, George Somlo

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Abstract

The possibility of an association between primary hyperparathyroidism and breast cancer has been postulated. We report here a sibship with three premenopausal breast cancers and hyperparathyroidism, and no detectable BRCA or MEN1 gene mutations. We explore genetic and molecular rationales for an association between these metabolic and neoplastic processes.

Somlo G, Chow W, Hamasaki V et al (2001) Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. Biol Blood Marrow Transplant 7(5):284–293. doi:10.1053/bbmt.2001.v7.pm11400951 PubMedCrossRef

Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef

Heath H, Hodgson SF, Kennedy MA (1980) Primary hyperparathyroidism incidence, morbidity and potential economic impact in the community. N Engl J Med 302(4):189–193PubMed

Marx SJ (2005) Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5(5):367–375. doi:10.1038/nrc1610 PubMedCrossRef

Dreijerink KM, Mulder KW, Winkler GS et al (2006) Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 66(9):4929–4935. doi:10.1158/0008-5472.CAN-05-4461 PubMedCrossRef

Corte MD, Tamargo F, Alvarez A et al (2006) Cytosolic levels of TFF1/pS2 in breast cancer: their relationship to clinical-pathological parameters and their prognostic significance. Breast Cancer Res Treat 96(1):63–72. doi:10.1007/s10549-005-9041-7 PubMedCrossRef

Ghataorhe P, Kurian AW, Pickart A et al (2007) A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Cancer Genet Cytogenet 179(2):89–92. doi:10.1016/j.cancergencyto.2007.08.009 PubMedCrossRef

Yoshimoto K, Endo H, Tsuyuguchi M et al (1998) Familial isolated primary hyperparathyroidism with parathyroid carcinomas: clinical and molecular features. Clin Endocrinol (Oxf) 48:67–72. doi:10.1046/j.1365-2265.1998.00354.x CrossRef

Warner J, Epstein M, Sweet A et al (2004) Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet 41(3):155–160. doi:10.1136/jmg.2003.016725 PubMedCrossRef

10.

Klein RD, Salih S, Bessoni J et al (2005) Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet Med 7(2):131–138. doi:10.1097/01.GIM.0000153663.62300.F8 PubMedCrossRef

11.

Nilsson IL, Zedenius J, Yin L et al (2007) The association between primary hyperparathyroidism and malignancy: nationwide cohort on cancer incidence after parathyroidectomy. Endocr Relat Cancer 14(1):135–140. doi:10.1677/erc.1.01261 PubMedCrossRef

12.

Fierabracci P, Pinchera A, Miccoli P et al (2001) Increased prevalence of primary hyperparathyroidism in treated breast cancer. J Endocrinol Invest 24(5):315–320PubMed

13.

Axelrod DM, Bockman RS, Wong GY et al (1987) Distinguishing features of primary hyperparathyroidism in patients with breast cancer. Cancer 60(7):1620–1624. doi:10.1002/1097-0142(19871001)60:7≤1620::AID-CNCR2820600733≥3.0.CO;2-3PubMedCrossRef

14.

Kristensen B, Mouridsen HT, Holmegaard SN et al (1989) Amelioration of postmenopausal primary hyperparathyroidism during adjuvant tamoxifen for breast cancer. Cancer 64(9):1965–1967. doi:10.1002/1097-0142(19891101)64:9≤1965::AID-CNCR2820640933≥3.0.CO;2-GPubMedCrossRef

15.

Almquist M, Manjer J, Bondeson L et al (2007) Serum calcium and breast cancer risk: results form a prospective cohort study of 7,847 women. Cancer Causes Control 18:595–602. doi:10.1007/s10552-007-9001-0 PubMedCrossRef

16.

Birch MA, Carron JA, Scott M et al (1995) Parathryoid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines. Br J Cancer 721:90–95

17.

Hoey RP, Sanderson C, Iddon J et al (2003) The parathyroid-hormone related protein receptor is expressed in bone metastases and promotes autocrine proliferation of breast cancer cells. Br J Cancer 884:567–573. doi:10.1038/sj.bjc.6600757 CrossRef

18.

Bianchi GV, Loibl S, Zamagni C et al (2007) Phase II multicenter trial of sorafenib in the treatment of patients with metastatic breast cancer. Proc Amer Soc Clin Oncol Breast Cancer Symposium 2007 (Abstract #164)

19.

Liu L, Cao Y, Chen C et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66(24):11851–11858. doi:10.1158/0008-5472.CAN-06-1377 PubMedCrossRef

20.

Nishioka C, Ikeoze T, Yang J et al (2007) Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk Res (epub ahead of print.)

21.

Koyama M, Matsuzaki Y, Yogosawa S et al (2007) ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther 6(5):1579–1587. doi:10.1158/1535-7163.MCT-06-0814 PubMedCrossRef

Title: An association between invasive breast cancer and familial idiopathic hyperparathyroidism: a case series and review of the literature
Authors: Sumanta Kumar Pal
Kathleen Blazer
Jeffrey Weitzel
George Somlo
Publication date: 01-05-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0056-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer

PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity

Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition

Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics

No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study

Disruption of estrogen receptor α-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer